Search

Your search keyword '"Tiling, Reinhold"' showing total 172 results
Start Over Author "Tiling, Reinhold"
172 results on '"Tiling, Reinhold"'

1. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours

Author

Beyer, Leonie, Gosewisch, Astrid, Lindner, Simon, Völter, Friederike, Mittlmeier, Lena M., Tiling, Reinhold, Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Rübenthaler, Johannes, Auernhammer, Christoph J., Spitzweg, Christine, Böning, Guido, Gildehaus, F. J., Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Wenter, Vera, Todica, Andrei, Bartenstein, Peter, and Ilhan, Harun

Published
2021
Full Text
View/download PDF

6. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Author

Eschbach, Ralf S., primary, Hofmann, Markus, additional, Späth, Lukas, additional, Sheikh, Gabriel T., additional, Delker, Astrid, additional, Lindner, Simon, additional, Jurkschat, Klaus, additional, Wängler, Carmen, additional, Wängler, Björn, additional, Schirrmacher, Ralf, additional, Tiling, Reinhold, additional, Brendel, Matthias, additional, Wenter, Vera, additional, Dekorsy, Franziska J., additional, Zacherl, Mathias J., additional, Todica, Andrei, additional, Ilhan, Harun, additional, Grawe, Freba, additional, Cyran, Clemens C., additional, Unterrainer, Marcus, additional, Rübenthaler, Johannes, additional, Knösel, Thomas, additional, Paul, Tanja, additional, Boeck, Stefan, additional, Westphalen, Christoph Benedikt, additional, Spitzweg, Christine, additional, Auernhammer, Christoph J., additional, Bartenstein, Peter, additional, Unterrainer, Lena M., additional, and Beyer, Leonie, additional

Published
2023
Full Text
View/download PDF

10. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE

Author

Eschbach, Ralf, primary, Hofmann, Markus, additional, Späth, Lukas, additional, Unterrainer, Lena M., additional, Sheihk, Gabriel T, additional, Delker, Astrid, additional, Lindner, Simon, additional, Jurkschat, Klaus, additional, Wängler, Carmen, additional, Wängler, Björn, additional, Schirrmacher, Ralf, additional, Tiling, Reinhold, additional, Brendel, Matthias, additional, Wenter, Vera, additional, Dekorsy, Franziska J., additional, Zacherl, Mathias J, additional, Todica, Andrei, additional, Ilhan, Harun, additional, Grawe, Freba, additional, Cyran, Clemens C., additional, Unterrainer, Marcus, additional, Rübenthaler, Johannes, additional, Knösel, Thomas, additional, Paul, Tanja, additional, Boeck, Stefan, additional, Westphalen, C. Benedikt, additional, Spitzweg, Christine, additional, Auernhammer, Christoph J., additional, Bartenstein, Peter, additional, and Beyer, Leonie, additional

Published
2022
Full Text
View/download PDF

11. Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SiTATE.

Author

Eschbach, Ralf S., Hofmann, Markus, Späth, Lukas, Sheikh, Gabriel T., Delker, Astrid, Lindner, Simon, Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Tiling, Reinhold, Brendel, Matthias, Wenter, Vera, Dekorsy, Franziska J., Zacherl, Mathias J., Todica, Andrei, Ilhan, Harun, Grawe, Freba, Cyran, Clemens C., and Unterrainer, Marcus

Subjects
SOMATOSTATIN receptors, NEUROENDOCRINE tumors, SOMATOSTATIN, POSITRON emission tomography, ADRENAL glands
Abstract

Purpose: Somatostatin analogues (SSA) are frequently used in the treatment of neuroendocrine tumours. Recently, [18F]SiTATE entered the field of somatostatin receptor (SSR) positron emission tomography (PET)/computed tomography (CT) imaging. The purpose of this study was to compare the SSR-expression of differentiated gastroentero-pancreatic neuroendocrine tumours (GEP-NET) measured by [18F]SiTATE-PET/CT in patients with and without previous treatment with long-acting SSAs to evaluate if SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT. Methods: 77 patients were examined with standardised [18F]SiTATE-PET/CT within clinical routine: 40 patients with long-acting SSAs up to 28 days prior to PET/CT examination and 37 patients without pre-treatment with SSAs. Maximum and mean standardized uptake values (SUVmax and SUVmean) of tumours and metastases (liver, lymphnode, mesenteric/peritoneal and bones) as well as representative background tissues (liver, spleen, adrenal gland, blood pool, small intestine, lung, bone) were measured, SUV ratios (SUVR) were calculated between tumours/metastases and liver, likewise between tumours/metastases and corresponding specific background, and compared between the two groups. Results: SUVmean of liver (5.4 ± 1.5 vs. 6.8 ± 1.8) and spleen (17.5 ± 6.8 vs. 36.7 ± 10.3) were significantly lower (p < 0.001) and SUVmean of blood pool (1.7 ± 0.6 vs. 1.3 ± 0.3) was significantly higher (p < 0.001) in patients with SSA pre-treatment compared to patients without. No significant differences between tumour-to-liver and specific tumour-to-background SUVRs were observed between both groups (all p > 0.05). Conclusion: In patients previously treated with SSAs, a significantly lower SSR expression ([18F]SiTATE uptake) in normal liver and spleen tissue was observed, as previously reported for 68Ga-labelled SSAs, without significant reduction of tumour-to-background contrast. Therefore, there is no evidence that SSA treatment needs to be paused prior to [18F]SiTATE-PET/CT. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Dosimetry and optimal scan time of [18F]SiTATE-PET/CT in patients with neuroendocrine tumours.

Author

Beyer, Leonie, Gosewisch, Astrid, Lindner, Simon, Völter, Friederike, Mittlmeier, Lena M., Tiling, Reinhold, Brendel, Matthias, Cyran, Clemens C., Unterrainer, Marcus, Rübenthaler, Johannes, Auernhammer, Christoph J., Spitzweg, Christine, Böning, Guido, Gildehaus, F. J., Jurkschat, Klaus, Wängler, Carmen, Wängler, Björn, Schirrmacher, Ralf, Wenter, Vera, and Todica, Andrei

Subjects
NEUROENDOCRINE tumors, RADIATION dosimetry, SOMATOSTATIN receptors, INJECTIONS, ADULTS, OPTICALLY stimulated luminescence
Abstract

Purpose: Radiolabelled somatostatin analogues targeting somatostatin receptors (SSR) are well established for combined positron emission tomography/computer tomography (PET/CT) imaging of neuroendocrine tumours (NET). [18F]SiTATE has recently been introduced showing high image quality, promising clinical performance and improved logistics compared to the clinical reference standard 68Ga-DOTA-TOC. Here we present the first dosimetry and optimal scan time analysis. Methods: Eight NET patients received a [18F]SiTATE-PET/CT (250 ± 66 MBq) with repeated emission scans (10, 30, 60, 120, 180 min after injection). Biodistribution in normal organs and SSR-positive tumour uptake were assessed. Dosimetry estimates for risk organs were determined using a combined linear-monoexponential model, and by applying 18F S-values and reference target masses for the ICRP89 adult male or female (OLINDA 2.0). Tumour-to-background ratios were compared quantitatively and visually between different scan times. Results: After 1 h, normal organs showed similar tracer uptake with only negligible changes until 3 h post-injection. In contrast, tracer uptake by tumours increased progressively for almost all types of metastases, thus increasing tumour-to-background ratios over time. Dosimetry resulted in a total effective dose of 0.015 ± 0.004 mSv/MBq. Visual evaluation revealed no clinically relevant discrepancies between later scan times, but image quality was rated highest in 60 and 120 min images. Conclusion: [18F]SiTATE-PET/CT in NET shows overall high tumour-to-background ratios from 60 to 180 min after injection and an effective dose comparable to 68Ga-labelled alternatives. For clinical use of [18F]SiTATE, the best compromise between image quality and tumour-to-background contrast is reached at 120 min, followed by 60 min after injection. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

36. Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT

Author

Hartenbach, Markus, primary, Weber, Stefan, additional, Albert, Nathalie L., additional, Hartenbach, Sabrina, additional, Hirtl, Albert, additional, Zacherl, Mathias J., additional, Paprottka, Philipp M., additional, Tiling, Reinhold, additional, Bartenstein, Peter, additional, Hacker, Marcus, additional, and Haug, Alexander R., additional

Published
2015
Full Text
View/download PDF

37. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy

Author

Graute, Vera, Jansen, Nathalie, Uebleis, Christopher, Seitz, Michael, Hartenbach, Markus, Scherr, Michael, Thieme, Sven, Cumming, Paul, Klanke, Katharina, Tiling, Reinhold, Bartenstein, Peter, Hacker, Marcus, Graute, Vera, Jansen, Nathalie, Uebleis, Christopher, Seitz, Michael, Hartenbach, Markus, Scherr, Michael, Thieme, Sven, Cumming, Paul, Klanke, Katharina, Tiling, Reinhold, Bartenstein, Peter, and Hacker, Marcus

Abstract

Purpose The aim of the present study was to identify prostate-specific antigen (PSA) threshold levels, as well as PSA velocity, progression rate and doubling time in relation to the detectability and localization of recurrent lesions with [18F]fluorocholine (FC) PET/CT in patients after radical prostatectomy. Methods The study group comprised 82 consecutive patients with biochemical relapse after radical prostatectomy. PSA levels measured at the time of imaging were correlated with the FC PET/CT detection rates in the entire group with PSA velocity (in 48 patients), with PSA doubling time (in 47 patients) and with PSA progression (in 29 patients). Results FC PET/CT detected recurrent lesions in 51 of the 82 patients (62%). The median PSA value was significantly higher in PET-positive than in PET-negative patients (4.3 ng/ml vs. 1.0 ng/ml; p < 0.01). The optimal PSA threshold from ROC analysis for the detection of recurrent prostate cancer lesions was 1.74 ng/ml (AUC 0.818, 82% sensitivity, 74% specificity). Significant differences between PET-positive and PET-negative patients were found for median PSA velocity (6.4 vs. 1.1 ng/ml per year; p < 0.01) and PSA progression (5.0 vs. 0.3 ng/ml per year, p < 0.01) with corresponding optimal thresholds of 1.27 ng/ml per year and 1.28 ng/ml per year, respectively. The PSA doubling time suggested a threshold of 3.2 months, but this just failed to reach statistical significance (p = 0.071). Conclusion In a study cohort of patients with biochemical recurrence of prostate cancer after radical prostatectomy there emerged clear PSA thresholds for the presence of FC PET/CT-detectable lesions.

Published
2012

38. Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy

Author

Graute, Vera, primary, Jansen, Nathalie, additional, Übleis, Christopher, additional, Seitz, Michael, additional, Hartenbach, Markus, additional, Scherr, Michael Karl, additional, Thieme, Sven, additional, Cumming, Paul, additional, Klanke, Katharina, additional, Tiling, Reinhold, additional, Bartenstein, Peter, additional, and Hacker, Marcus, additional

Published
2011
Full Text
View/download PDF

41. 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine Tumors

Author

Haug, Alexander R., primary, Auernhammer, Christoph J., additional, Wängler, Björn, additional, Schmidt, Gerwin P., additional, Uebleis, Christopher, additional, Göke, Burkhard, additional, Cumming, Paul, additional, Bartenstein, Peter, additional, Tiling, Reinhold, additional, and Hacker, Marcus, additional

Published
2010
Full Text
View/download PDF

43. Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose

Author

Schwarz-Dose, Jörg, primary, Untch, Michael, additional, Tiling, Reinhold, additional, Sassen, Stefanie, additional, Mahner, Sven, additional, Kahlert, Steffen, additional, Harbeck, Nadia, additional, Lebeau, Annette, additional, Brenner, Winfried, additional, Schwaiger, Markus, additional, Jaenicke, Fritz, additional, and Avril, Norbert, additional

Published
2009
Full Text
View/download PDF

47. F-18-Fluoro-2-Deoxyglucose Positron Emission Tomography/Computed Tomography in the Follow-up of Breast Cancer With Elevated Levels of Tumor Markers

Author

Haug, Alexander Robert, primary, Schmidt, Gerwin Paul, additional, Klingenstein, Annemarie, additional, Heinemann, Volker, additional, Stieber, Petra, additional, Priebe, Markus, additional, la Fougère, Christian, additional, Becker, Christoph, additional, Hahn, Klaus, additional, and Tiling, Reinhold, additional

Published
2007
Full Text
View/download PDF

50. Sixty-four slice spiral CT angiography does not predict the functional relevance of coronary artery stenoses in patients with stable angina

Author

Hacker, Marcus, primary, Jakobs, Tobias, additional, Hack, Nicolas, additional, Nikolaou, Konstantin, additional, Becker, Christoph, additional, von Ziegler, Franz, additional, Knez, Andreas, additional, König, Andreas, additional, Klauss, Volker, additional, Reiser, Maximilian, additional, Hahn, Klaus, additional, and Tiling, Reinhold, additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results